The CMT Research Foundation announce a new project with Samsara Therapeutics, a US/UK-based biotech company that is developing a novel class of drugs for CMT1A.
CMT1A is caused by duplication of a stretch of DNA that includes the PMP22 gene, and people with CMT1A produce approximately […]
Continue Reading